Sang G, Shao Q, Zhang L
Zhejiang Academy of Medical Sciences, Hangzhou 310013.
Zhonghua Fu Chan Ke Za Zhi. 1999 Jun;34(6):331-4.
To investigate the effectiveness and side-effects of different doses of mifepristone alone or in combination with anordrin given orally within 96 hours after unprotected intercourse as an emergency contraceptive.
2,400 cases of healthy women were recruited and allocated randomly in 4 groups: single dose of 25 mg mifepristone, 25 mg mifepristone plus 7.5 mg anordrin, 10 mg mifepristone plus 5 mg anordrin and 10 mg mifepristone alone. The efficacy rates of contraception were estimated according to Dixon method.
The total expected number of pregnancy was 171.9 for 2,387 subjects enrolled in the study. The number of observed pregnancies related to method failure was 32 cases. The contraceptive effectiveness rates for the above 4 groups were 80.9%, 85.3%, 90.6% and 67.3%, respectively. For the group received 10 mg mifepristone plus 5 mg anordrin, pregnancy rate was 0.7% which was significantly lower than that in 10 mg mifepristone alone group (2.2%, P < 0.05). The incidences of withdrawal bleeding were 9.2%, 4.9%, 3.4% and 6.7% for the 4 group respectively. Two groups received mifepristone in combination with anordrin showed significant lower incidence of withdrawal bleeding than those in mifepristone alone groups.
Single oral administration of 25 mg mifepristone alone, and the combination of 10 mg mifepristone plus 5 mg anordrin were safe and effective treatment regimen for emergency contraception with no serious adverse reaction and disturbance on menstrual pattern.
探讨在无保护性交后96小时内口服不同剂量米非司酮单独使用或与双炔失碳酯联合使用作为紧急避孕方法的有效性和副作用。
招募2400例健康女性,随机分为4组:单剂量25mg米非司酮组、25mg米非司酮加7.5mg双炔失碳酯组、10mg米非司酮加5mg双炔失碳酯组和单独10mg米非司酮组。采用Dixon法评估避孕有效率。
本研究纳入的2387名受试者中,预计妊娠总数为171.9例。与方法失败相关的观察到的妊娠数为32例。上述4组的避孕有效率分别为80.9%、85.3%、90.6%和67.3%。对于接受10mg米非司酮加5mg双炔失碳酯的组,妊娠率为0.7%,显著低于单独10mg米非司酮组(2.2%,P<0.05)。4组的撤退性出血发生率分别为9.2%、4.9%、3.4%和6.7%。两组米非司酮与双炔失碳酯联合使用的撤退性出血发生率显著低于单独使用米非司酮组。
单次口服25mg米非司酮以及10mg米非司酮加5mg双炔失碳酯联合使用是安全有效的紧急避孕治疗方案,对月经模式无严重不良反应和干扰。